AIIMS: No clear evidence that plasma therapy lowers mortality risk

Updated: 07 August, 2020 09:14 IST | Agencies | New Delhi

Interim analysis of a controlled trial was done at AIIMS to assess the efficacy of this mode of treatment

Officers of the state police department wearing face masks take part in a rehearsal ahead of the upcoming Independence Day parade in Kolkata. PIC/AFP
Officers of the state police department wearing face masks take part in a rehearsal ahead of the upcoming Independence Day parade in Kolkata. PIC/AFP

Convalescent plasma therapy did not show benefit in reducing mortality risk among COVID-19 patients, according to an interim analysis of a randomised controlled trial done at AIIMS here to assess the efficacy of this mode of treatment. The therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those into an active Coronavirus infected patient to help kickstart the immune system to fight back the infection.

AIIMS Director Dr Randeep Guleria told PTI on Thursday no clear mortality benefit of convalescent plasma therapy was seen during a trial conducted among 30 COVID-19 patients. During the trial, one group of patients was given convalescent plasma therapy along with the standard supportive treatment while the other group only received standard treatment. The number of fatalities recorded in both the groups was equal and there was not much clinical improvement in the condition of patients, he said.

Telangana clears draft policy for jobs to locals

The state Cabinet on Wednesday approved the draft policy under which the majority share of employment would be given to the local residents in industries that are established in Telangana. The Cabinet headed by Chief Minister K Chandrasekhar Rao discussed the draft policy prepared by the industries department headed by Industries Minister KT Rama Rao. The Cabinet felt that the local residents should have more opportunities in the industries being set up in the state. It also decided to give incentives to the industries which provide more job opportunities to the locals.

Glenmark to launch 400mg FabiFlu

Glenmark Pharmaceuticals announced that it is set to introduce a 400 mg version of oral antiviral — FabiFlu — for the treatment of mild to moderate COVID-19 in India. It was the first Indian company to commercially launch an antiviral drug — Favipiravir with brand name FabiFlu — for the treatment of COVID-19. The company received marketing and manufacturing approval from the Drug Controller General of India and launched the product.

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/ reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

First Published: 07 August, 2020 06:50 IST

Sign up for all the latest news, top galleries and trending videos from

loading image
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK